IL310225A - Recombinant mycobacterium as an immunotherapeutic agent for the second-line therapy of bladder carcinoma - Google Patents

Recombinant mycobacterium as an immunotherapeutic agent for the second-line therapy of bladder carcinoma

Info

Publication number
IL310225A
IL310225A IL310225A IL31022524A IL310225A IL 310225 A IL310225 A IL 310225A IL 310225 A IL310225 A IL 310225A IL 31022524 A IL31022524 A IL 31022524A IL 310225 A IL310225 A IL 310225A
Authority
IL
Israel
Prior art keywords
immunotherapeutic agent
bladder carcinoma
line therapy
recombinant mycobacterium
mycobacterium
Prior art date
Application number
IL310225A
Other languages
Hebrew (he)
Original Assignee
Serum Life Science Europe Gmbh
Serum Inst India Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP21187253.6A external-priority patent/EP4122491A1/en
Priority claimed from US17/667,784 external-priority patent/US20220160858A1/en
Application filed by Serum Life Science Europe Gmbh, Serum Inst India Ltd filed Critical Serum Life Science Europe Gmbh
Publication of IL310225A publication Critical patent/IL310225A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL310225A 2021-07-22 2022-07-20 Recombinant mycobacterium as an immunotherapeutic agent for the second-line therapy of bladder carcinoma IL310225A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163224575P 2021-07-22 2021-07-22
EP21187253.6A EP4122491A1 (en) 2021-07-22 2021-07-22 Recombinant microbacterium as an immunotherapeutic agent for the second-line therapy of bladder carcinoma
US17/667,784 US20220160858A1 (en) 2015-05-04 2022-02-09 Recombinant Mycobacterium as an Immunotherapeutic Agent for the Treatment of Cancer
PCT/EP2022/070373 WO2023001895A1 (en) 2021-07-22 2022-07-20 Recombinant mycobacterium as an immunotherapeutic agent for the second-line therapy of bladder carcinoma

Publications (1)

Publication Number Publication Date
IL310225A true IL310225A (en) 2024-03-01

Family

ID=82846547

Family Applications (1)

Application Number Title Priority Date Filing Date
IL310225A IL310225A (en) 2021-07-22 2022-07-20 Recombinant mycobacterium as an immunotherapeutic agent for the second-line therapy of bladder carcinoma

Country Status (4)

Country Link
AU (1) AU2022313491A1 (en)
CA (1) CA3224671A1 (en)
IL (1) IL310225A (en)
WO (1) WO2023001895A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733151A (en) 1996-08-23 1998-03-31 Edsall; David Electrical clamping connection device
AUPO761697A0 (en) 1997-06-30 1997-07-24 Cardiac Crc Nominees Pty Limited Process for the purification of polyethers
BRPI0409789B8 (en) 2003-04-23 2021-05-25 Max Planck Gesellschaft bacterial cell, its preparation processes and its use, composition, and process for the preparation of a live vaccine
BR112013015882B8 (en) 2010-12-21 2021-01-05 Max Planck Gesellschaft recombinant cell of mycobacterium bovis (m. bovis) from bacillus calmette-guérin (bcg) of the danish strain plague subtype and use of it
EP3090757A1 (en) 2015-05-04 2016-11-09 Vakzine Projekt Management GmbH Recombinant mycobacterium as an immunotherapeutic agent for the treatment of cancer

Also Published As

Publication number Publication date
AU2022313491A1 (en) 2024-01-18
CA3224671A1 (en) 2023-01-26
WO2023001895A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
EP3941810A4 (en) Safety integrated personal mobility vehicle
IL281586A (en) Compositions and methods for manufacturing gene therapy vectors
PL3620479T3 (en) Tin-free catalysis of silane-functional polyurethane crosslinking agents
IL310225A (en) Recombinant mycobacterium as an immunotherapeutic agent for the second-line therapy of bladder carcinoma
IL279609A (en) Bifunctional compositions for the treatment of cancer
GB201919428D0 (en) Immunotherapeutic treatment of cancer
EP4010022A4 (en) Compositions and methods for diagnosis and treatment of bladder cancer
EP3755711A4 (en) Immunotherapeutic composition for the treatment of cancer
HK1247574A1 (en) Recombinant mycobacterium as an immunotherapeutic agent for the treatment of cancer
SG11202100478VA (en) Single cellular diagnosis of primary vitreoretinal lymphoma
IL281997A (en) Combination therapy for the treatment of uveal melanoma
IL281281A (en) Combination therapy for the treatment of prostate cancer
SG11202011434SA (en) Methods for the treatment of bladder cancer
IL291351A (en) Compositions for the treatment of solid tumors
EP4199961A4 (en) Combination immunotherapy methods for the treatment of cancer
GB202306292D0 (en) Methods and compositions for cellular therapy
IL283031A (en) Vibegron for the treatment of overactive bladder symptoms
SG11202107618WA (en) Mobile device for treatment of itching, having an interface
EP3987032A4 (en) Methods and compositions for the treatment of cancer
IL263905A (en) Combination therapy of cancer
EP4082563A4 (en) Post-operation adjuvant therapy agent
EP4028043A4 (en) An immunotherapeutic for prostate cancer treatment
MX2017015191A (en) Hybrid scorch retardant/cure co-agent.
EP4008509C0 (en) Foamed biogranulate grains
GB202101665D0 (en) Methods and compositions for cellular therapy